Denovicon seamlessly integrates AI, machine learning, generative therapeutic design, and physics-based approaches (e.g., quantum chemistry, statistical mechanics, molecular dynamics, and free-energy methods) into its (hybrid) computational drug discovery platform. With it, a vast amount of chemical space (~10²⁷ molecules) is quickly and accurately triaged, while only the most desirable analogs are transformed into clinical candidates. We are currently focused on small-molecule therapeutics for a variety of targets in the DNA damage response (DDR) pathways and immuno-oncology. In particular, we are progressing first-in-class molecules that selectively target PARP1 and PARP2 for various diseases in oncology, immunology, neuroscience, and cardiovascular, as well as PARP7 for multiple oncology indications.